Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences Stem Cells for Drug Discovery & Toxicity Screening 2017

Norio Nakatsuji's Biography



Norio Nakatsuji, Chief Advisor, Stem Cell & Device Laboratory, Inc. (SCAD); Professor Emeritus, Kyoto University

Professor Norio Nakatsuji is a graduate from Kyoto University. He obtained postdoctoral training in Sweden, USA and UK. He became a professor at National Institute of Genetics in 1991. In 1999, He moved to the Institute for Frontier Medical Sciences at Kyoto University and became its director from 2003 to 2007. His laboratory established monkey ES cell lines in 2000 and human ES cell lines in 2003, which were distributed to other scientists. He is also a scientific founder of a start-up company, ReproCELL, Inc., which accomplished successful IPO in 2013. From 2007, He is the founding director of Kyoto University’s Institute for Integrated Cell-Material Sciences (iCeMS), an institute which aims to advance cross-disciplinary research and technological innovation, including stem cell R&D utilizing chemical compounds and functional materials. He became a Professor Emeritus of Kyoto University in 2015. He took a leadership in government-supported projects carried out by collaboration between technology-oriented companies and academic groups. In 2014, he founded two start-up companies, Kyoto Stem Cell Innovation, Inc (SCI) and Stem Cell & Device Laboratory, Inc. (SCAD). He is a Director and Chief Advisor of SCI and SCAD. SCAD is aiming at development of innovative products by integration of stem cell technology and nanotechnology/micro-engineering, with a focus on human pluripotent stem cells (ES/iPS cells). It develops and supplies high quality cell and micro-tissue products for drug screening and drug safety assay as well as cell therapy.

Norio Nakatsuji Image

3D Cell-Material Micro-Tissue Devices in Application of ES/iPS Cells for Drug Screening/Toxicology and Cell Therapy

Monday, 10 July 2017 at 16:30

Add to Calendar ▼2017-07-10 16:30:002017-07-10 17:30:00Europe/London3D Cell-Material Micro-Tissue Devices in Application of ES/iPS Cells for Drug Screening/Toxicology and Cell TherapyStem Cells for Drug Discovery and Toxicity Screening 2017 in Boston, USABoston, USASELECTBIOenquiries@selectbiosciences.com

SCAD is a start-up company founded in 2014 based on the integration of stem cell technology and nanotechnology/micro-engineering developed at Kyoto University.  We are currently focusing on the iPSC-derived cardiomyocytes, with possible addition of neurons and hepatocytes. Cardiomyocytes derived from human pluripotent stem cells (hPSC-CMs) are promising materials for drug screening/toxicology and cell therapy. However, there are two major issues: immaturity of hPSC-CMs and instability of cardiac cellular function. To overcome these issues, we use two technologies: the robust cardiac differentiation method and aligned nanofibers as a culture scaffold. Our cardiac differentiation method can efficiently generate cardiomyocytes from any hPSC lines under cytokine-free defined condition. The hPSC-CMs seeded on nanofiber scaffolds formed 3D multilayered structures (Micro-Tissues), which show upregulated expression of cardiac maturation marker genes and enhanced and stable cardiac cell functions. Our micro-tissue devices are easy to handle and highly useful for drug screening/toxicology assays.


Add to Calendar ▼2017-07-10 00:00:002017-07-11 00:00:00Europe/LondonStem Cells for Drug Discovery and Toxicity Screening 2017Stem Cells for Drug Discovery and Toxicity Screening 2017 in Boston, USABoston, USASELECTBIOenquiries@selectbiosciences.com